Mawar Karsa

Sydney, NSW 2052, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

NAD Metabolism in Acute Myeloid Leukaemia: Biological Rationale and Therapeutic Opportunities.

NAD Metabolism in Acute Myeloid Leukaemia: Biological Rationale and Therapeutic Opportunities.

Journal: Nutrients

Published: May 19, 2026

BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemia.

BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemia.

Journal: British journal of haematology

Published: October 26, 2025

Polyamine depletion limits progression of acute leukaemia.

Polyamine depletion limits progression of acute leukaemia.

Journal: International journal of cancer

Published: July 23, 2024

The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma.

The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma.

Journal: Molecular oncology

Published: January 25, 2024

FDA-approved disulfiram as a novel treatment for aggressive leukemia.

FDA-approved disulfiram as a novel treatment for aggressive leukemia.

Journal: Journal of molecular medicine (Berlin, Germany)

Published: May 26, 2023

Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.

Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.

Journal: Science translational medicine

Published: May 17, 2023

Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias.

Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias.

Journal: Clinical and translational medicine

Published: February 15, 2022

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.

Journal: Frontiers in oncology

Published: January 27, 2022

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia.

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia.

Journal: Frontiers in oncology

Published: September 20, 2021

Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.

Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 30, 2020

Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.

Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.

Journal: British journal of cancer

Published: January 29, 2020

Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.

Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.

Journal: Leukemia

Published: May 30, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026